Johnson & Johnson (JNJ) Q2 2026 Earnings
GAAP EPS of $2.27 includes $1,245M intangible asset amortization, $267M litigation-related charges, $276M restructuring charges (including $200M for new Innovative Medicine supply chain restructuring), $258M Orthopaedics separation costs, $80M acquisition/integration/divestiture costs, and $(213)M gains on securities
How Did JNJ Stock React to Q2 2026 Earnings?
S&P 500 over the same 30 days: +2.85%.
Did JNJ Beat Earnings? Q2 2026 Results
Yes. Johnson & Johnson reported Q2 2026 earnings of $2.90 a share on Jul 15, 2026, beating the $2.85 consensus estimate by 1.8%. Revenue was $25.3B against a $25.1B estimate.
Johnson & Johnson delivered a clean beat across both top and bottom lines in the second quarter of 2026, with adjusted EPS of $2.90 edging past the $2.85 consensus by 1.59% and revenue of $25.31 billion clearing estimates by roughly 1% while growing 6.6% year over year. The standout driver was the Innovative Medicine segment, where oncology revenues surged 17.3% to $7.41 billion on the back of blockbuster contributions from DARZALEX at $4.21 billion and explosive growth from cell therapy franchise entries CARVYKTI and TALVEY, more than offsetting a steep 55.2% decline in STELARA as biosimilar competition intensifies. TREMFYA's 72.5% leap to $2.05 billion added further momentum, while MedTech contributed $8.93 billion in sales with broad-based gains across cardiovascular and orthopaedics. Management responded to the strong quarter by raising full-year 2026 adjusted EPS guidance by $0.13 to a range of $11.60 to $11.75, and lifting the revenue outlook to $100.80 billion to $101.40 billion, reflecting confidence in the company's diversified growth profile at a time when some peers in medical devices are trimming their own full-year forecasts.
- DARZALEX worldwide sales grew 18.9% to $4.2B, driven by strong demand across indications
- TREMFYA sales surged 72.5% to $2.0B driven by ongoing share gains and label expansions
- Oncology portfolio growth of 17.3% led by DARZALEX, CARVYKTI, TECVAYLI, RYBREVANT/LAZCLUZE, and TALVEY
- CARVYKTI grew 49.4% to $657M reflecting expanding commercial availability
- CAPLYTA grew 70.9% to $361M following acquisition of Intra-Cellular Therapies
- SPRAVATO grew 40.8% to $584M in Neuroscience
- U.S. Innovative Medicine sales grew 8.9% operationally
- Shockwave grew 14.6% in MedTech Cardiovascular
- STELARA biosimilar erosion: sales declined 55.2% (approximately 760 basis points drag on Innovative Medicine growth)
“Johnson & Johnson delivered strong second-quarter results, demonstrating the power of our innovation, the depth of our portfolio and the momentum in our pipeline as we advance transformative treatments that address the world's toughest health challenges.”
Johnson & Johnson CEO, on the earnings call
What Is Johnson & Johnson's Outlook?
Johnson & Johnson raised its full-year 2026 guidance. Estimated reported sales are now $100.8B–$101.4B (midpoint $101.1B), representing 7.0%–7.6% growth (midpoint 7.3%), up from the prior April 2026 guidance of $100.3B–$101.3B. Adjusted EPS (diluted) guidance was raised by $0.13 to $11.60–$11.75 (midpoint $11.68), representing 7.5%–8.9% growth (midpoint 8.2%). Adjusted operational EPS guidance was raised by $0.18 to $11.50–$11.65 (midpoint $11.58), representing 6.6%–8.0% growth (midpoint 7.3%). Adjusted operational sales growth is now expected at 6.2%–6.8% (midpoint 6.5%), up from 5.6%–6.6% previously. The July 2026 guidance uses an illustrative Euro average rate of $1.15.
JNJ YoY Financials
| Metric | Q2 2026 | Q2 2025 | Year over year |
|---|---|---|---|
| Revenue | $25.3B | $23.7B | +6.6% |
| Gross Profit | $17.3B | $16.1B | +7.1% |
| Operating Income | $6.7B | $6.8B | −0.9% |
| Net Income | $5.5B | $5.5B | −0.0% |
JNJ Revenue by Segment
JNJ Revenue by Geography
Figures from SEC filings and company reports. Not investment advice.